<DOC>
	<DOC>NCT01492166</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard速 30 NovoLet速 used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.</brief_summary>
	<brief_title>Observational Study on Efficacy, Safety and Convenience of Using Mixtard速 30 NovoLet速 Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin, pork; isophane insulin, pork drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes Not adequately controlled on their current therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>